Espislogen closed $12.5M Series B round

Epsilogen Ltd secured £30.75 million (approximately $41.20 million) in an oversubscribed Series B financing round. The round was led by new investor Novartis Venture Fund and joined by new investors 3B Future Health Fund, British Patient Capital, Schroders Capital, and Caribou Property, alongside founding investor Epidarex Capital and ALSA Ventures. Subsequently, Epsilogen announced a £12.5 million Series B expansion financing, bringing the total Series B funds raised to £43.25 million, with participation from existing investors including British Patient Capital, Novartis Venture Fund, Epidarex Capital, 3B Future Health Fund, and ALSA Ventures.

Epsilogen is a global leader in the development of novel immunoglobulin E (IgE) antibodies designed to treat cancer. The company plans to use the proceeds from the financing to advance the clinical development of its lead drug candidate, MOv18 IgE, in platinum-resistant ovarian cancer, and to support the further development of its pipeline of IgE-based antibody candidates and its proprietary IGEG™ antibody platform.